Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.73 |
| ▸ | FLT1 | P17948 | 5/20 | 0.62 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.57 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | PRKACA | P17612 | 1/20 | 0.56 |
| ▸ | LTK | P29376 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8593958 | 0.99 | EGFR (0.72) | EGFRFLT1KDRPRKD1TGFBR1 | |
| SCHEMBL8093519 | 0.85 | EGFR (1.00) | EGFRFLT1ERBB2PIK3CAPIK3CG | |
| SCHEMBL1733829 | 0.84 | EGFR (0.76) | EGFRFLT1KDRERBB2PIK3CA | |
| SCHEMBL27545981 | 0.84 | EGFR (0.69) | EGFRFLT1KDRERBB2PIK3CA | |
| SCHEMBL7535216 | 0.84 | EGFR (0.65) | EGFRFLT1KDRPRKD1ERBB2 | |
| SCHEMBL31514622 | 0.84 | EGFR (0.69) | EGFRFLT1KDRERBB2PIK3CA | |
| SCHEMBL30302532 | 0.83 | EGFR (0.58) | EGFRFLT1KDRPRKD1TGFBR1 | |
| SCHEMBL22803770 | 0.83 | EGFR (0.58) | EGFRFLT1KDRPRKD1TGFBR1 | |
| SCHEMBL7976688 | 0.83 | EGFR (0.67) | EGFRFLT1KDRMETERBB2 | |
| SCHEMBL7983292 | 0.83 | EGFR (0.67) | EGFRFLT1KDRPRKD1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029696-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
| EP-1877397-B1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF EGF AND/OR ERBB2 RECEPTOR TYROSINE KINASE | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| US-20090023759-A1 | Quinazoline Derivatives as Inhibitors of EGF and/or erbB2 Receptor Tyrosine Kinase | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1940825-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1877397-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF EGF AND/OR ERBB2 RECEPTOR TYROSINE KINASE | AstraZeneca AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| EP-1858885-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007034143-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| WO-2006117521-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF EGF AND/OR ERBB2 RECEPTOR TYROSINE KINASE | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006092574-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
| US-6391872-B1 | SENSITIVE TO ADRENERGIC ANTAGONIST | PFIZER INC | 2002-05-21 | — | — | US | disclosed |
| EP-1028946-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999023077-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023759-A1 | Quinazoline Derivatives as Inhibitors of EGF and/or erbB2 Receptor Tyrosine Kinase | ERBB2, EGFR, ERBB3 | EGFR 2/4885FLT1 21/4885KDR 8/4885 |
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ABL1, ERBB2, CDK2 | EGFR 7/4885FLT1 93/4885KDR 19/4885 |
| US-20100029696-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ERBB2, ABL1, MKI67 | EGFR 4/4885FLT1 49/4885KDR 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.